Trial Profile

A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Lintuzumab Ac-225 (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Actinium Pharmaceuticals

Most Recent Events

19 Jul 2023 Status changed from not yet recruiting to withdrawn prior to enrolment as study was postponed.
16 Feb 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Dec 2023.
16 Feb 2022 Planned initiation date changed from 1 Sep 2021 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com